About Ronald Hunt
Ronald Hunt is a director at Abcuro.
Ronald Hunt reports to the SEC as a director or major shareholder of 15 public companies, including Rallybio (RLYB), Iterum Therapeutics plc (ITRM) and Harpoon Therapeutics (HARP).
Ronald Hunt first appears on SEC filings in 2008.
Experience
This experience comes from SEC filings. The years are when the filings name Ronald Hunt in the role, so the role may have started earlier or lasted longer.
Abcuro, Inc.
Director
2026 · Newton, MA
Develops immunotherapies for people with autoimmune diseases and cancer.
RC
Rallybio Corp
Director
2021 – 2026 · Public company (RLYB)
IP
Iterum Therapeutics plc
Director and 10% owner
2018 – 2025 · Public company (ITRM)
HI
Harpoon Therapeutics, Inc.
Director and 10% owner
2019 – 2024 · Public company (HARP)
NI
Neuronetics, Inc.
Director and 10% owner
2018 – 2019 · Public company (STIM)
II
iRhythm Holdings, Inc.
10% owner
2016 · Public company (IRTC)
LI
Lite Strategy, Inc.
10% owner
2012 – 2015 · Public company (LITS)
AI
Aravive, Inc.
10% owner
2014 · Public company (ARAV)
DI
Durata Therapeutics, Inc.
Director and 10% owner
2012 – 2014 · Public company (DRTX)
CI
Chimerix Inc.
10% owner
2014 · Public company (CMRX)
CI
Concert Pharmaceuticals, Inc.
10% owner
2014 · Public company (CNCE)
OP
Oxford Immunotec Global PLC
10% owner
2013 · Public company (OXFD)
RI
Relypsa Inc
Director and 10% owner
2013 · Public company (RLYP)
WC
World Heart Corp.
10% owner
2008 – 2012 · Public company (WHRT)
II
Icagen Inc.
Reporting person
2011 · Public company (ICGN)
PI
Paratek Pharmaceuticals, Inc.
10% owner
2009 – 2011 · Public company (PRTK)
Key Colleagues at Startups
The people Ronald Hunt works with at each company, as listed on that company's latest Form D.
Abcuro, Inc. · Form D, Aug 13, 2026
JM
John Martin
Chief Executive Officer and director
Michael Dybbs
Partner, Samsara BioCapital and director
Ming Fang
Managing Director, Redmile Group
Mark Pruzanski
Chairman of the Board
Sarah Boyce
Director